drugset

drugset / Trial / NCT00224393

Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis

NCT00224393 ↗

Phase 2 Completed 60 enrolled The Cleveland Clinic

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy of Enbrel in patients with primary systemic Amyloidosis.

Timeline

Start: 2001-02
Primary completion: —
Completion: 2005-08-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Etanercept	Protein / enzyme biologic	—	—

Indications